Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $151.
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $151.